甘草酸二铵肠溶胶囊防治肝功能损害的临床研究

发布时间：2017-12-28 22:35

本文关键词：甘草酸二铵肠溶胶囊防治肝功能损害的临床研究　出处：《基因组学与应用生物学》2016年08期 　论文类型：期刊论文

【摘要】：本研究对甘草酸二铵肠溶胶囊防治抗结核药物对肝功能损害临床疗效的前瞻性进行分析。统计分析2013年1月至2014年12月期间的180例结核病患者的临床资料。在本次研究中,观察组患者治疗2周、1个月和2个月后的肝功能损伤发生率为1.11%、5.56%和13.33%,对照组的发生率为7.78%、17.78%和30.00%(p0.05)。观察组与对照组患者治疗后的肝功能指标(谷丙转氨酶,谷草转氨酶,总胆红素)与治疗前比较有显著差异(p0.05)。且治疗后的观察组与对照组患者的肝功能指标对比分析,有显著差异(p0.05)。通过相关分析表明抗结核疾病的治疗中,使用甘草酸二铵肠溶胶囊治疗,可以显著的降低对患者肝功能产生的损伤,促进结核疾病的顺利进行,并提高治疗成功率。
[Abstract]:This study prospectively analyzed the clinical efficacy of Diammonium Glycyrrhizinate Enteric-coated Capsules for the prevention and treatment of anti tuberculosis drugs on liver function damage. The clinical data of 180 patients with tuberculosis from January 2013 to December 2014 were statistically analyzed. In this study, the incidence of liver function injury in the observation group was 1.11%, 5.56% and 13.33% after treatment for 2 weeks, 1 months and 2 months, respectively. The incidence of control group was 7.78%, 17.78% and 30% (P0.05). The observation group and the control group of patients with liver function indexes after treatment (alanine aminotransferase, aspartate aminotransferase, total bilirubin) have significant difference compared with before treatment (P0.05). There was a significant difference between the observation group and the control group after the treatment (P0.05). Through correlation analysis, the use of Diammonium Glycyrrhizinate Enteric-coated Capsules in the treatment of antitubercular diseases can significantly reduce the damage to liver function, promote the progression of tuberculosis and improve the success rate of treatment.
【作者单位】：齐鲁医药学院附属医院淄博市第一医院;
【分类号】：R52;R575
【正文快照】： Clinical Study of Diammonium Glycyrrhizinate Enteric-coated Capsules inthe Prevention of Liver DamageSun Jing*Hospital Affiliated to Qilu Medical College,Zibo First Hospital,Zibo,255200*Corresponding author,244958386@qq.com近几年,结核病的发病率不断的升高

【相似文献】